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Nickle et al. [1] recently reported a computational method
for HIV-1 vaccine antigen design; here we compare this
method with our previously published vaccine antigen design
method [2], using several criteria that we believe to be
important for a successful vaccine candidate [2]. The intent of
both approaches is to design a set of vaccine antigens that
could protect against diverse circulating strains of HIV-1 by
eliciting broad T cell responses. T cells recognize short
peptides of 8–12 amino acids, called epitopes, that are
presented on the surface of infected cells by human HLA
proteins. HIV-1 is highly variable, and both vaccine methods
[1,2] attempt to provide coverage of most common variants of
epitope-length fragments in HIV-1 proteins [3].
The two methods use very different computational
strategies, but both achieve high coverage of potential
epitopes. The COTþ method generates an antigen set
consisting of one full-length synthetic sequence
supplemented by a set of sequence fragments [1]. Initially, the
Center of Tree (COT) sequence is computed based on a
maximum likelihood phylogenetic tree inferred for a set of
test sequences [4]. The ‘‘center’’ of the tree is identiﬁed as the
point that minimizes the distances to the terminal branches,
and the evolutionary model and tree topology are used to
reconstruct the most likely sequence at that center point of
the tree [4]. Like an inferred most recent common ancestral
sequence [5], a COT sequence is an estimate of an historical
entity, based on a concatenation of the most likely nucleotide
at each position. The COTþ antigen design method uses the
COT sequence as a foundation, and builds on it by sequential
addition of protein fragments selected to provide enhanced
potential epitope coverage [6]. These fragments are selected
using a sliding window across all sequences; peptides are
scored by the level of additional coverage they provide, and
the highest-scoring fragments are added to the set, with
fragments being overlapped where possible. The result is the
COTþ sequence set: the full-length COT sequence plus a set
of additional sequence fragments of varying lengths (Table 1,
Figure 1). The summed length of all fragments are considered
in units of ‘‘protein lengths’’; Nickle et al. [1] illustrate the use
of two protein lengths of peptides in addition to the COT
protein, for a total of three gene length equivalents. They also
provide an option of assembling the fragments into linear
proteins (but this provided reduced population coverage
relative to the basic COTþ method) [1].
In contrast, the mosaic method that we recently described
[2] assembles a speciﬁed number of full-length protein
sequences that in combination optimize coverage of epitope
length peptides in a population. This method creates intact
HIV proteins that have the potential for natural expression
and processing of epitopes. We employed a genetic algorithm
to generate sets of sequences by in silico recombination of
natural protein sequences. Starting with randomly
recombined natural sequences, the algorithm proceeds by a
series of iterations of recombination and selection,
optimizing for 9-mer coverage of the input sequences. The
result is a small set of full-length protein sequences that
collectively approach the upper bound on coverage
attainable for a given number of proteins [2].
We designed a three-mosaic protein set using the same
input data as Nickle et al. to directly compare the two
methods using the same metric as Nickle et al. The mosaic set,
despite being constrained to use full-length proteins,
performed slightly better in terms of 9-mer coverage than
three protein lengths using COTþ (Figure 2). The mosaics
used three full-length protein sequences, however, compared
to 38 fragments for Gag and 15 for Nef included in the
optimal coverage COTþ antigen design (Figure 1, Table 1).
The processing of antigens that ultimately results in the
presentation of epitopes is not completely understood.
Therefore, a critical issue for the COTþ method is a strategy
for assembling the peptide fragments into antigens that
would be practical for vaccine delivery. It is possible to simply
concatenate the fragments, but this creates large numbers of
spurious 9-mers at the junctions (up to eight at each junction;
see Table 1), and may impact processing of embedded
epitopes in the context of the assembled fragments.
Some recent experimental results illustrate that problems
can occur at unnatural boundaries in polyproteins. We
initially designed mosaic protein sets for Env, Gag, Pol, and
Nef [2], although we highlighted creating mosaics from Gag
and the conserved center of Nef [2]. Nef is highly variable, but
is relatively conserved near the center of the protein, where
the most intense and frequent T cell responses have been
observed in the setting of natural infection [7]. Therefore, we
excluded the variable regions of Nef and generated a single
fusion protein comprising a mosaic full-length Gag plus the
relatively conserved center of Nef. The Gagþcentral Nef
fusion gene construct was cloned into a DNA vaccine vector
and transfected into 293T cells. Protein expression was
evaluated by Western blot analysis using HIV-speciﬁc MAbs
(241-D, Gag; 6.2 and EH1, Nef). The mosaic polyprotein was
larger than a Gag protein, as expected, and Gag-speciﬁc
cellular immune responses were detected by IFN-c Elispot
assay in splenocytes from mice immunized with this
polyprotein construct; however, Nef-speciﬁc responses were
Table 1. Number of Proteins or Protein Fragments Included in
the Antigen Design, and the Number of Rare or Unique 9-mers in
Various Protein Sets
Antigen Set Rare 9-mers
(n , 3)
Unnatural 9-mers
(n ¼ 0)
Number of
Fragments
Gag COTþ 45 3 3 8
Gag COTþ concatenated 6 324 3
3 Gag Mosaics 0 0 3
Nef COTþ 95 1 5
Nef COTþ concatenated 11 90 3
3 Nef Mosaics 0 0 3
doi:10.1371/journal.pcbi.0040015.t001
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protein as coating antigens in an ELISA, we detected anti-Gag
but not anti-Nef antibody responses in these mice. Thus,
this Gag/Nef fusion construct expresses Gag and elicits
Gag-speciﬁc immune responses, but does not induce anti-Nef
antibody orT cell responsesin vivo.These resultsdemonstrate
that unnatural linking of polypeptides can have unexpected
and undesirable consequences, and that appropriate assembly
of peptides can be a nontrivial endeavor.
Another important aspect of mosaic protein design is the
explicit exclusion of unnatural or very rare epitope-length
fragments [2]. While the excellent coverage of Mosaics
illustrates that this approach captures more rare variants
than other approaches (such as combining optimized natural
strains or sets of consensus sequences) [1,2], unique or
extremely rare variants are excluded at a user-speciﬁed rarity
threshold. Including such fragments in a vaccine has the
potential to elicit T cell responses that are unlikely to provide
cross-protection against circulating strains, and could even
divert vaccine-induced T cell responses from conserved
epitopes that are relevant for protection. We therefore set a
threshold such that all nine amino acid–length fragments that
are incorporated into mosaic proteins are found a minimum
of three times in the input data. In contrast, despite
algorithmic ‘‘smoothing’’ [1], the COTþ protein fragments
contain multiple rare and unnatural 9-mers (Table 1).
An exciting potential of this type of strategy is that it may
provide an approach for making a global HIV vaccine. We
previously compared mosaic vaccine design at three levels:
regional, within-subtype, and global [2]; in contrast, COTþwas
initially applied only to the B subtype [1]. The C subtype
regional comparison was based on a large South African
sequence dataset [8] compared to the non–South African
C subtype Los Alamos database sequences; there was no
discernable advantage in creating a South African–speciﬁc
mosaic versus a global C subtype mosaic vaccine in terms of
coverage of South African diversity [2]. We then compared
B and C subtype mosaics with mosaics designed for the entire
HIV-1 M group. We found that optimizing using one HIV
subtype results in a dramatic reduction in coverage of other
doi:10.1371/journal.pcbi.0040015.g001
Figure 1. Relative Locations and Sequence Identities of Potential Vaccine Antigens
The COTþcandidate vaccine sets represent one full-length COT protein plus numerous discrete sequence fragments located in various positions relative
to the intact Gag protein; mosaics are full-length ‘‘native-like’’ proteins. For the COTþsequence sets, the sequence on the top line is the COT sequence;
additional peptide fragments are numbered by addition order, and plotted by location from N-terminus to C-terminus. Gag sequences are presented in
two parts. For the mosaic sets, the sequence in the top line was arbitrarily chosen from the set, as the mosaics are designed as a combination of strains.
For all sequence sets, amino acid residues identical to those in the top line sequence are shown with a black background; differences from the first
sequence are shown in color, with different colors representing different amino acid classes; white space is used to represent gaps. The COTþantigen
sequences [1] were generously provided by J. I. Mullins.
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also see Figure 2E for a COT comparison). In contrast, mosaics
designed using a large and representative set of M group
proteinsfromtheLosAlamosdatabasegaveonlyslightlylower
coverage for any given subtype compared to within-subtype
optimized mosaics [2]—the tradeoff for this relatively small
loss of coverage is the potential for much broader (i.e., global)
coverage. In Figure 2C, we show the 9-mer coverage of the M
group Gag mosaics designed using the global set of M group
sequences from the Los Alamos database. Coverage is
comparable (within a few percent) for all subtypes tested [2]
as well as for the test set from Nickle et al. [1] (Figure 2D).
In conclusion, although the COTþmethod is an interesting
and algorithmically creative suggestion for vaccine design,
the Mosaic approach has several advantages. Nickle et al. [1]
note that ‘‘more computational intensive approaches such as
doi:10.1371/journal.pcbi.0040015.g002
Figure 2. Comparisons of 9-mer Coverage for the COTþ and Mosaic Antigen Designs
To allow direct methodological comparison, mosaic antigen sets were generated as in Fischer et al. [2], but based on the test set of 169 sequences used
in Nickle et al. [1] for Nef (A) and Gag (B,D). Potential epitope coverage provided by the combination of proteins is indicated by the percentage of
perfectly matched 9-mers in the protein alignment (red), the addition of those that match in 8/9 amino acids (orange), and the further addition of those
that match in 7/9 amino acids (yellow). Three full-length mosaic proteins provide slightly better coverage than three gene lengths of COTþ protein
fragments. For this class of methods, coverage may generally be improved by increasing the number of antigens, but with diminishing returns and at
the cost of increased vaccine complexity and expense; the best strategy must realistically balance these factors. Previously published mosaic sequences
(based on 551 Los Alamos sequences spanning the entire M group [2]) were scored against the 169-sequence Gag set (C), and the M group (E). To
directly compare the coverage of each antigen set to subtypes other than B, the COTþantigen set and the M-group mosaics were also scored against
an M-group dataset from which all B-clade sequences had been removed (F).
The M-group mosaic coverage of non-B clade proteins is 4%–5% less than the M-group coverage of B clade (C,F). Predictably, interclade coverage of the
B-clade–optimized antigens drops dramatically (81% ! 51% for COTþ, F; B-clade mosaics slightly less reduced ([2], unpublished data). For the M-group
global mosaics, in contrast, coverage is roughly equal for all clades; coverage of B-clade sequences by M-group mosaics is only 6%–7% below that of
specific B-clade–optimized mosaics (B,C), and coverage of non-B sequences remains relatively high (F).
All computer code for creating mosaics and assessing coverage, our previously designed mosaic antigens, and the datasets used were made publicly
accessible upon the original publication [2].
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on the problem of antigen design.’’ Indeed, we have already
applied such an approach and were able to achieve levels of
coverage approaching the achievable upper bound, without
sacriﬁcing the linear protein sequence, and with the
advantage of excluding rare epitope-length variants [2].
In contrast, the antigen sets generated by the COTþ method
are either fragmented pieces of protein, or a subset of those
fragments joined in a linear protein sequence that provides
suboptimal coverage [1]. The most important result of our
mosaic vaccine study is that it may provide a tractable
approach for global vaccine design: high coverage of viral
variability is presented in a feasible number of intact antigens
for a vaccine cocktail. &
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Comparison of Immunogen Designs
That Optimize Peptide Coverage:
Reply to Fischer et al.
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Vladimir Jojic, Darko Kirovski, Morgane Rolland,
Sergei Kosakovsky Pond, James I. Mullins
In our paper ‘‘Coping with Viral Diversity in HIV Vaccine
Design’’ [1], we presented several approaches to incorporate
viral variability within vaccine immunogens, including judi-
cious choice of natural strains. Most of our approaches
included at least one collinear gene length corresponding to
the Center-of-Tree (COT) sequence, which has near-optimal
peptide coverage for a single gene. Inclusion of a COT
sequence and optimizing the rest of the immunogen for
coverage, as suggested in [2], yielded a construct (COTþ) with
the greatest coverage of peptide diversity, minimally sacri-
ficing peptide coverage in comparison with unconstrained
diversity optimization. Fischer et al. [3] introduced mosaics—
a different approach to increasing coverage while maintain-
ing collinearity using an optimization algorithm based on
simulated recombination.
In their response to Nickle et al. [1], Fischer et al. [4] suggest
that maintaining full collinearity of viral gene sequences with
native viral proteins is the only tractable approach to
producing immunogens inclusive of viral variability. This
claim was based on the observation that mosaics had slightly
higher coverage than COTþ at 33 and 43 strain lengths,
despite the fact that all mosaic components are constrained
to be collinear with the full gene. However, as we pointed out,
a variety of optimization algorithms can be used to perform
coverage optimization, with computationally intensive
approaches typically yielding better results. Figure 1
compares the coverage of mosaics with COTþ constructs
produced by two optimization algorithms—the simple greedy
extension described in Nickle et al. [1], which can be
implemented in hours and run in seconds on any modern
personal computer, and the more complex combinatiorial
optimization approach of [5] run for one day on a cluster of
300 PCs. We also include the coverage of a construct
optimized without any collinearity constraints, derived
using the Kirovski et al. [5] algorithm. The coverage of
COTþ created by combinatorial optimization is greater than
that of mosaics, especially at larger lengths where even the
simple greedy algorithm surpasses the mosaic coverage.
Furthermore, the optimized COTþ coverage is almost
identical to the coverage of constructs optimized with no
collinearity constraints, indicating that the price for
imposing a constraint on the immunogen to include a
single virus-like strain is small.
Fischer and colleagues also argued that COTþ creates
unnatural peptide sequences by concatenation. However,
similar concatenation of their mosaics would have produced
about 18 unnatural 9-mer peptides. Furthermore, the COTþ
approach can be tuned to both penalize the introduction of
unnatural peptides on concatenation, and to deﬁne the
number of segments to be separately expressed, and thus
reduce the requirement for concatenation. Several
additional inferences were made in the response by Fischer
PLoS Computational Biology | www.ploscompbiol.org January 2008 | Volume 4 | Issue 1 | e15 | e25 0178et al. that should be commented upon. First, COTþ may, of
course, be optimized for arbitrary HIV clades or
combinations of clades, but the publication of our paper in
PLoS Computational Biology reﬂects our focus on approaches to
immunogen design rather than on the production of an
exhaustive series of constructs. Also, just as in the mosaic
approach, COTþ can be optimized to exclude rare variants
(referred to as smoothing in our paper).
Fischer et al. also discussed disappointing unpublished
ﬁndings on the immunogenicity induced against Nef by a
construct obtained by fusing a full-length Gag gene and the
centralportion oftheNef gene. However,theseresults canonly
befairlyassessedinlight ofwhatwould beexpectedforthe full-
lengthNefprotein,andinthecaseofcellularimmuneresponses,
in the context of the same MHC speciﬁcities. However, these
controls were not provided. We certainly agree that there are
substantialchallengestotheestablishmentofamultivalentCD8
response,yetmultiplestrategieshavebeenandarebeingdevised
to overcome this important problem. For example, different
groups have shown that CD8þ T cell responses can be
successfully elicited against CD8þ T cell epitope strings when
they are separated by short linker sequences and not in the
context of the native protein, implying that they can be
processed and presented in vivo [6–11].
Finally, despite 25 years of AIDS research and intensive yet
uniformly failed efforts to develop an AIDS vaccine, the
scientiﬁc community is poorly positioned to determine
which, if any, approach to vaccine immunogen design will
prove successful. Thus, arguing over methodologies
developed with the same goal of incorporating variability
has little signiﬁcance as long as we do not know whether
maximizing variability or inclusion of the entire full-length
viral proteins are valid strategies. It may very well be that
removing certain epitopes could be a more judicious
approach than an overall epitope maximization strategy
[12]. Indeed, the ﬂexibility afforded by the COTþ approach,
which is not limited to full-length proteins, may well prove
superior to immunization with full-length viral protein
immunogens. &
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